<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 10 Aug 2023 14:08:10 +0000</lastbuilddate>
<pubDate>Thu, 10 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Transcatheter aortic valve implantation in patients with severe aortic stenosis and cardiogenic shock: an important step forward</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37559255/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 10:ehad471. doi: 10.1093/eurheartj/ehad471. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37559255/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37559255</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad471>10.1093/eurheartj/ehad471</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37559255</guid>
<pubDate>Thu, 10 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Bernard D Prendergast</dc:creator>
<dc:creator>Tiffany Patterson</dc:creator>
<dc:creator>Simon Redwood</dc:creator>
<dc:date>2023-08-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter aortic valve implantation in patients with severe aortic stenosis and cardiogenic shock: an important step forward</dc:title>
<dc:identifier>pmid:37559255</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad471</dc:identifier>
</item>
<item>
<title>Reply: Anticoagulation in Noncritically Ill Patients Hospitalized With COVID-19</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):e59-e60. doi: 10.1016/j.jacc.2023.04.059.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558380</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.059>10.1016/j.jacc.2023.04.059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558380</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Michael E Farkouh</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Anticoagulation in Noncritically Ill Patients Hospitalized With COVID-19</dc:title>
<dc:identifier>pmid:37558380</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.059</dc:identifier>
</item>
<item>
<title>Challenges Before Considering Full-Dose Anticoagulation in Noncritically Ill Patients With COVID-19</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):e57. doi: 10.1016/j.jacc.2023.05.053.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558379</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.053>10.1016/j.jacc.2023.05.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558379</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mehmet Agirbasli</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Challenges Before Considering Full-Dose Anticoagulation in Noncritically Ill Patients With COVID-19</dc:title>
<dc:identifier>pmid:37558379</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.053</dc:identifier>
</item>
<item>
<title>Outcomes of Hospitalized COVID-19 Patients: SARS-CoV-2 Variants and Vaccination Status Are Important Confounders of Results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):e55. doi: 10.1016/j.jacc.2023.03.431.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558378</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.03.431>10.1016/j.jacc.2023.03.431</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558378</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ori Wand</dc:creator>
<dc:creator>Keren Cohen-Hagai</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Outcomes of Hospitalized COVID-19 Patients: SARS-CoV-2 Variants and Vaccination Status Are Important Confounders of Results</dc:title>
<dc:identifier>pmid:37558378</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.03.431</dc:identifier>
</item>
<item>
<title>Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>Among statin-treated patients, inflammation assessed by means of high-sensitivity C-reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all-cause mortality than low-density-lipoprotein cholesterol (LDL-C). Several therapies that target residual inflammatory risk significantly reduce vascular event rates. For coronary artery disease patients already taking guideline-directed medical care, including statins, low-dose colchicine (0.5 mg/d orally) has been shown to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Among statin-treated patients, inflammation assessed by means of high-sensitivity C-reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all-cause mortality than low-density-lipoprotein cholesterol (LDL-C). Several therapies that target residual inflammatory risk significantly reduce vascular event rates. For coronary artery disease patients already taking guideline-directed medical care, including statins, low-dose colchicine (0.5 mg/d orally) has been shown to safely lower major adverse cardiovascular events by 31% among those with stable atherosclerosis and by 23% after recent myocardial infarction. These magnitudes of benefit are larger than those seen in contemporary secondary prevention trials of adjunctive lipid-lowering agents. Low-dose colchicine is contraindicated in patients with significant renal or liver dysfunction and should be temporarily discontinued when taking concomitant agents such as clarithromycin, ketoconazole, and cyclosporine that share metabolism pathways. Lipid lowering and inflammation inhibition are not in conflict but are synergistic. In the future, combined use of aggressive LDL-C-lowering and inflammation-inhibiting therapies may become standard of care for most atherosclerosis patients. In June 2023, the U.S. Food and Drug Administration approved the use of low-dose colchicine to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558377/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558377</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.055>10.1016/j.jacc.2023.05.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558377</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Kyle Nelson</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37558377</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.055</dc:identifier>
</item>
<item>
<title>Management of Infants With Tetralogy of Fallot: Questioning Conventional Wisdom</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558376/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):628-630. doi: 10.1016/j.jacc.2023.06.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558376/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558376</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.008>10.1016/j.jacc.2023.06.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558376</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Barry A Love</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Management of Infants With Tetralogy of Fallot: Questioning Conventional Wisdom</dc:title>
<dc:identifier>pmid:37558376</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.008</dc:identifier>
</item>
<item>
<title>Pulmonary Artery Hypoplasia in Neonates With Tetralogy of Fallot</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558375/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Despite perception, the presence of hPA in neonates with sTOF conferred no increase in overall hazard of mortality or reintervention after definitive repair. PA growth was superior in the hPA cohort. These findings suggest that the presence of hPA does not adversely impact outcomes in sTOF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):615-627. doi: 10.1016/j.jacc.2023.05.051.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Neonates with symptomatic tetralogy of Fallot (sTOF) with hypoplastic pulmonary arteries (hPA) are considered high risk. Data are needed to inform the impact of hPA on outcomes, and the ideal management strategy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The objectives of this study were to quantify the impact of hPA on outcomes in neonates with sTOF and measure the impact of strategy on pulmonary artery (PA) growth in this population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Neonates with sTOF from 2005 to 2017 were reviewed from the Congenital Cardiac Research Collaborative. Criteria for hPA included a unilateral PA z score &lt;-2.0 and contralateral PA z score &lt;0. Primary outcome was mortality. Secondary outcomes included reintervention and PA growth.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We included 542 neonates with sTOF, including 188 (35%) with hPA and 354 (65%) with normal PA, with median follow-up of 4.1 years. Median right and left hPA z scores were -2.19 (25th-75th percentile: -2.55 to -1.94) and -2.23 (25th-75th percentile: -2.64 to -1.91), respectively. Staged repair (vs primary TOF repair) was less common in the hPA cohort (36 vs 44%; P = 0.07). Survival was similar between groups (unadjusted P = 0.16; adjusted P = 0.25). Reintervention was more common in the hPA group (HR: 1.28; 95% CI: 1.01-1.63; P = 0.044); there was no difference after definitive repair (HR: 1.21; 95% CI: 0.93-1.58; P = 0.16). PA growth at 1 year was greater in the hPA cohort, particularly for the right PA (P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Despite perception, the presence of hPA in neonates with sTOF conferred no increase in overall hazard of mortality or reintervention after definitive repair. PA growth was superior in the hPA cohort. These findings suggest that the presence of hPA does not adversely impact outcomes in sTOF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558375/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558375</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.051>10.1016/j.jacc.2023.05.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558375</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Christopher J Petit</dc:creator>
<dc:creator>Andrew C Glatz</dc:creator>
<dc:creator>Andrew B Goldstone</dc:creator>
<dc:creator>Mark A Law</dc:creator>
<dc:creator>Jennifer C Romano</dc:creator>
<dc:creator>Shiraz A Maskatia</dc:creator>
<dc:creator>Paul J Chai</dc:creator>
<dc:creator>Jeffrey D Zampi</dc:creator>
<dc:creator>Jeffery J Meadows</dc:creator>
<dc:creator>George T Nicholson</dc:creator>
<dc:creator>Shabana Shahanavaz</dc:creator>
<dc:creator>Athar M Qureshi</dc:creator>
<dc:creator>Courtney E McCracken</dc:creator>
<dc:creator>Christopher E Mascio</dc:creator>
<dc:creator>Sarosh P Batlivala</dc:creator>
<dc:creator>Ivor B Asztalos</dc:creator>
<dc:creator>Steven J Healan</dc:creator>
<dc:creator>Justin D Smith</dc:creator>
<dc:creator>Joelle A Pettus</dc:creator>
<dc:creator>Asaad Beshish</dc:creator>
<dc:creator>James E B Raulston</dc:creator>
<dc:creator>Krissie M Hock</dc:creator>
<dc:creator>Amy L Pajk</dc:creator>
<dc:creator>Bryan H Goldstein</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Pulmonary Artery Hypoplasia in Neonates With Tetralogy of Fallot</dc:title>
<dc:identifier>pmid:37558375</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.051</dc:identifier>
</item>
<item>
<title>A Look Beyond the Sports Field: A Paradigm of Shared Decision Making in Everyday Life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558374/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):612-614. doi: 10.1016/j.jacc.2023.06.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558374/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558374</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.020>10.1016/j.jacc.2023.06.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558374</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Shankar Baskar</dc:creator>
<dc:creator>Richard J Czosek</dc:creator>
<dc:creator>David S Spar</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Look Beyond the Sports Field: A Paradigm of Shared Decision Making in Everyday Life</dc:title>
<dc:identifier>pmid:37558374</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.020</dc:identifier>
</item>
<item>
<title>Fatal Cardiac Arrhythmias During Electronic Gaming in Patients With Genetically Mediated Heart Diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Although anecdotal cases of electronic gaming-associated life-threatening arrhythmias have been reported, in this largest single-center study to date, we show that these are extremely rare occurrences. While electronic gaming can have adverse health consequences, the threat of electronic gaming-triggered sudden death should not be used to try to curb time spent gaming.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):603-611. doi: 10.1016/j.jacc.2023.06.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Recently, electronic gaming has been reported as a precipitant of life-threatening cardiac arrhythmias in susceptible individuals. However, the prevalence of cardiac events in genetic heart diseases (GHDs) in the setting of electronic gaming has not been established.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this study, we sought to define the prevalence of cardiac events occurring in the setting of electronic gaming in GHDs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Retrospective review of all patients evaluated and treated at Mayo Clinic's genetic heart rhythm clinic from July 2000 to November 2022 was performed to identify patients with a history of playing electronic games at the time of their cardiac event. Cardiac event was used to define events occurring before diagnosis, and breakthrough cardiac event (BCE) was used for events occurring after diagnosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 3,370 patients with a GHD (mean age at first evaluation 27 ± 19 years, 55% female), 1,079 (32%) had a cardiac event before diagnosis, with 5 patients (0.5%) having an electronic gaming-associated event (3 catecholaminergic polymorphic ventricular tachycardia, 1 long QT syndrome, and 1 premature ventricular contraction-triggered ventricular fibrillation). After diagnosis and treatment, 431 patients (13%) experienced ≥1 BCE during follow-up, of which 1 electronic gaming-associated BCE (0.2%) occurred in a patient with catecholamine-sensitive right outflow tract ventricular tachycardia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Although anecdotal cases of electronic gaming-associated life-threatening arrhythmias have been reported, in this largest single-center study to date, we show that these are extremely rare occurrences. While electronic gaming can have adverse health consequences, the threat of electronic gaming-triggered sudden death should not be used to try to curb time spent gaming.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558373</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.019>10.1016/j.jacc.2023.06.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558373</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Raquel Neves</dc:creator>
<dc:creator>Sahej Bains</dc:creator>
<dc:creator>J Martijn Bos</dc:creator>
<dc:creator>Ciorsti J MacIntyre</dc:creator>
<dc:creator>John R Giudicessi</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Fatal Cardiac Arrhythmias During Electronic Gaming in Patients With Genetically Mediated Heart Diseases</dc:title>
<dc:identifier>pmid:37558373</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.019</dc:identifier>
</item>
<item>
<title>Subcutaneous ICD in Congenital Heart Disease: Will Skin Deep Cut It?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):600-602. doi: 10.1016/j.jacc.2023.06.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558372</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.011>10.1016/j.jacc.2023.06.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558372</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Louise Harris</dc:creator>
<dc:creator>Melanie R Burg</dc:creator>
<dc:creator>Douglas Y Mah</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Subcutaneous ICD in Congenital Heart Disease: Will Skin Deep Cut It?</dc:title>
<dc:identifier>pmid:37558372</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.011</dc:identifier>
</item>
<item>
<title>Subcutaneous Implantable Cardioverter-Defibrillators in Patients With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In this nationwide study, patients with CHD represented 2% of all S-ICD implantations. Our findings emphasize the effectiveness and safety of S-ICD in this particularly high-risk population. (S-ICD French Cohort Study [HONEST]; NCT05302115).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):590-599. doi: 10.1016/j.jacc.2023.05.057.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Very few data have been published on the use of subcutaneous implantable cardioverter-defibrillators (S-ICDs) in patients with congenital heart disease (CHD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to analyze outcomes associated with S-ICDs in patients with CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This nationwide French cohort including all patients with an S-ICD was initiated in 2020 by the French Institute of Health and Medical Research. Characteristics at implantation and outcomes were analyzed in patients with CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From October 12, 2012, to December 31, 2019, among 4,924 patients receiving an S-ICD implant in 150 centers, 101 (2.1%) had CHD. Tetralogy of Fallot, univentricular heart, and dextro-transposition of the great arteries represented almost one-half of the population. Patients with CHD were significantly younger (age 37.1 ± 15.4 years vs 50.1 ± 14.9 years; P &lt; 0.001), more frequently female (37.6% vs 23.0%; P &lt; 0.001), more likely to receive an S-ICD for secondary prevention (72.3% vs 35.9%; P &lt; 0.001), and less likely to have severe systolic dysfunction of the systemic ventricle (28.1% vs 53.1%; P &lt; 0.001). Over a mean follow-up period of 1.9 years, 16 (15.8%) patients with CHD received at least 1 appropriate shock, with all shocks successfully terminating the ventricular arrhythmia. The crude risk of appropriate S-ICD shock was twice as high in patients with CHD compared with non-CHD patients (annual incidences of 9.0% vs 4.4%; HR: 2.1; 95% CI: 1.3-3.4); however, this association was no longer significant after propensity matching (especially considering S-ICD indication, P = 0.12). The burden of all complications (HR: 1.2; 95% CI: 0.7-2.1; P = 0.4) and inappropriate shocks (HR: 0.9; 95% CI: 0.4-2.0; P = 0.9) was comparable in both groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this nationwide study, patients with CHD represented 2% of all S-ICD implantations. Our findings emphasize the effectiveness and safety of S-ICD in this particularly high-risk population. (S-ICD French Cohort Study [HONEST]; NCT05302115).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558371</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.057>10.1016/j.jacc.2023.05.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558371</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Victor Waldmann</dc:creator>
<dc:creator>Christelle Marquié</dc:creator>
<dc:creator>Francis Bessière</dc:creator>
<dc:creator>David Perrot</dc:creator>
<dc:creator>Frédéric Anselme</dc:creator>
<dc:creator>Nicolas Badenco</dc:creator>
<dc:creator>Sergio Barra</dc:creator>
<dc:creator>Géraldine Bertaux</dc:creator>
<dc:creator>Hugues Blangy</dc:creator>
<dc:creator>Pierre Bordachar</dc:creator>
<dc:creator>Serge Boveda</dc:creator>
<dc:creator>Michel Chauvin</dc:creator>
<dc:creator>Nicolas Clémenty</dc:creator>
<dc:creator>Gaël Clerici</dc:creator>
<dc:creator>Nicolas Combes</dc:creator>
<dc:creator>Pascal Defaye</dc:creator>
<dc:creator>Jean-Claude Deharo</dc:creator>
<dc:creator>Philippe Durand</dc:creator>
<dc:creator>Guillaume Duthoit</dc:creator>
<dc:creator>Romain Eschalier</dc:creator>
<dc:creator>Laurent Fauchier</dc:creator>
<dc:creator>Rodrigue Garcia</dc:creator>
<dc:creator>Olivier Geoffroy</dc:creator>
<dc:creator>Edouard Gitenay</dc:creator>
<dc:creator>Jean-Baptiste Gourraud</dc:creator>
<dc:creator>Charles Guenancia</dc:creator>
<dc:creator>Laurence Iserin</dc:creator>
<dc:creator>Peggy Jacon</dc:creator>
<dc:creator>Laurence Jesel-Morel</dc:creator>
<dc:creator>Fawzi Kerkouri</dc:creator>
<dc:creator>Didier Klug</dc:creator>
<dc:creator>Linda Koutbi</dc:creator>
<dc:creator>Fabien Labombarda</dc:creator>
<dc:creator>Magalie Ladouceur</dc:creator>
<dc:creator>Gabriel Laurent</dc:creator>
<dc:creator>Christophe Leclercq</dc:creator>
<dc:creator>Baptiste Maille</dc:creator>
<dc:creator>Alice Maltret</dc:creator>
<dc:creator>Grégoire Massoulié</dc:creator>
<dc:creator>Pierre Mondoly</dc:creator>
<dc:creator>Sandro Ninni</dc:creator>
<dc:creator>Pierre Ollitrault</dc:creator>
<dc:creator>Jean-Luc Pasquié</dc:creator>
<dc:creator>Bertrand Pierre</dc:creator>
<dc:creator>Pénélope Pujadas</dc:creator>
<dc:creator>Laure Champ-Rigot</dc:creator>
<dc:creator>Frédéric Sacher</dc:creator>
<dc:creator>Nicolas Sadoul</dc:creator>
<dc:creator>Alexandre Schatz</dc:creator>
<dc:creator>Pierre Winum</dc:creator>
<dc:creator>Paul-Ursmar Milliez</dc:creator>
<dc:creator>Vincent Probst</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Subcutaneous Implantable Cardioverter-Defibrillators in Patients With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:37558371</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.057</dc:identifier>
</item>
<item>
<title>Septal Myectomy: An Evolving Therapy for Obstructive Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):587-589. doi: 10.1016/j.jacc.2023.05.054.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558370/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558370</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.054>10.1016/j.jacc.2023.05.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558370</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Hartzell V Schaff</dc:creator>
<dc:creator>Hao Cui</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Septal Myectomy: An Evolving Therapy for Obstructive Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:37558370</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.054</dc:identifier>
</item>
<item>
<title>First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37558369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: TA-BSM is a safe and efficient minimally invasive procedure for septal reduction of heterogeneous HOCM. Compared with conventional septal myectomy, TA-BSM provides real-time evaluation to guide resection while reducing surgical trauma. (Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy; NCT05332691).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 15;82(7):575-586. doi: 10.1016/j.jacc.2023.05.052.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: To simplify surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy (HOCM), we developed a novel transapical beating-heart septal myectomy (TA-BSM) procedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this study, we sought to evaluate the clinical utility of TA-BSM in a first-in-human trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with HOCM were enrolled if they presented with drug-refractory disabling symptoms. TA-BSM was performed via minithoracotomy with the use of our beating-heart myectomy device under echocardiographic guidance, without the use of cardiopulmonary bypass. Repeated resections were performed to tailor the extent of the septal myectomy for sufficient abolishment of left ventricular outflow tract (LVOT) obstruction and mitral regurgitation (MR). The primary outcome measure was procedural success, defined by resting/provoked LVOT gradient &lt;30/50 mm Hg and residual MR grade ≤1+ (of 4+) at 3-month follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 47 patients aged 12 to 77 years were enrolled. Of the 46 patients who were followed for 3 months, 42 achieved procedural success. The maximal LVOT gradient decreased from 86 mm Hg (IQR: 67-114 mm Hg) at baseline to 19 mm Hg (IQR: 14-28 mm Hg) at 3 months. MR grade was ≤1+ in 3 patients at baseline and in 45 patients at 3 months. One patient died on postoperative day 10 owing to device-unrelated reasons. Other major adverse events included 1 delayed ventricular septal perforation and 1 intraoperative left ventricular apical tear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TA-BSM is a safe and efficient minimally invasive procedure for septal reduction of heterogeneous HOCM. Compared with conventional septal myectomy, TA-BSM provides real-time evaluation to guide resection while reducing surgical trauma. (Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy; NCT05332691).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37558369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37558369</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.052>10.1016/j.jacc.2023.05.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37558369</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jing Fang</dc:creator>
<dc:creator>Yani Liu</dc:creator>
<dc:creator>Ying Zhu</dc:creator>
<dc:creator>Rui Li</dc:creator>
<dc:creator>Rui Wang</dc:creator>
<dc:creator>Dao Wen Wang</dc:creator>
<dc:creator>Yunhu Song</dc:creator>
<dc:creator>Chenhe Li</dc:creator>
<dc:creator>Yue Chen</dc:creator>
<dc:creator>Lin Cheng</dc:creator>
<dc:creator>Kangchao Zheng</dc:creator>
<dc:creator>Yun Zhao</dc:creator>
<dc:creator>Shiliang Li</dc:creator>
<dc:creator>Cai Cheng</dc:creator>
<dc:creator>Liming Xia</dc:creator>
<dc:creator>Xiaoping Chen</dc:creator>
<dc:creator>Song Wan</dc:creator>
<dc:creator>Xiang Wei</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy</dc:title>
<dc:identifier>pmid:37558369</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.052</dc:identifier>
</item>
<item>
<title>Molecular mechanism for Tn7-like transposon recruitment by a type I-B CRISPR effector</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37557170/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>Tn7-like transposons have co-opted CRISPR-Cas systems to facilitate the movement of their own DNA. These CRISPR-associated transposons (CASTs) are promising tools for programmable gene knockin. A key feature of CASTs is their ability to recruit Tn7-like transposons to nuclease-deficient CRISPR effectors. However, how Tn7-like transposons are recruited by diverse CRISPR effectors remains poorly understood. Here, we present the cryo-EM structure of a recruitment complex comprising the Cascade...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 1:S0092-8674(23)00743-2. doi: 10.1016/j.cell.2023.07.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Tn7-like transposons have co-opted CRISPR-Cas systems to facilitate the movement of their own DNA. These CRISPR-associated transposons (CASTs) are promising tools for programmable gene knockin. A key feature of CASTs is their ability to recruit Tn7-like transposons to nuclease-deficient CRISPR effectors. However, how Tn7-like transposons are recruited by diverse CRISPR effectors remains poorly understood. Here, we present the cryo-EM structure of a recruitment complex comprising the Cascade complex, TniQ, TnsC, and the target DNA in the type I-B CAST from Peltigera membranacea cyanobiont 210A. Target DNA recognition by Cascade induces conformational changes in Cas6 and primes TniQ recruitment through its C-terminal domain. The N-terminal domain of TniQ is bound to the seam region of the TnsC spiral heptamer. Our findings provide insights into the diverse mechanisms for the recruitment of Tn7-like transposons to CRISPR effectors and will aid in the development of CASTs as gene knockin tools.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37557170/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37557170</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.010>10.1016/j.cell.2023.07.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37557170</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Shukun Wang</dc:creator>
<dc:creator>Clinton Gabel</dc:creator>
<dc:creator>Romana Siddique</dc:creator>
<dc:creator>Thomas Klose</dc:creator>
<dc:creator>Leifu Chang</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Molecular mechanism for Tn7-like transposon recruitment by a type I-B CRISPR effector</dc:title>
<dc:identifier>pmid:37557170</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.010</dc:identifier>
</item>
<item>
<title>A membrane-associated MHC-I inhibitory axis for cancer immune evasion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37557169/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>Immune-checkpoint blockade has revolutionized cancer treatment, but some cancers, such as acute myeloid leukemia (AML), do not respond or develop resistance. A potential mode of resistance is immune evasion of T cell immunity involving aberrant major histocompatibility complex class I (MHC-I) antigen presentation (AP). To map such mechanisms of resistance, we identified key MHC-I regulators using specific peptide-MHC-I-guided CRISPR-Cas9 screens in AML. The top-ranked negative regulators were...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 2:S0092-8674(23)00783-3. doi: 10.1016/j.cell.2023.07.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Immune-checkpoint blockade has revolutionized cancer treatment, but some cancers, such as acute myeloid leukemia (AML), do not respond or develop resistance. A potential mode of resistance is immune evasion of T cell immunity involving aberrant major histocompatibility complex class I (MHC-I) antigen presentation (AP). To map such mechanisms of resistance, we identified key MHC-I regulators using specific peptide-MHC-I-guided CRISPR-Cas9 screens in AML. The top-ranked negative regulators were surface protein sushi domain containing 6 (SUSD6), transmembrane protein 127 (TMEM127), and the E3 ubiquitin ligase WWP2. SUSD6 is abundantly expressed in AML and multiple solid cancers, and its ablation enhanced MHC-I AP and reduced tumor growth in a CD8<sup>+</sup> T cell-dependent manner. Mechanistically, SUSD6 forms a trimolecular complex with TMEM127 and MHC-I, which recruits WWP2 for MHC-I ubiquitination and lysosomal degradation. Together with the SUSD6/TMEM127/WWP2 gene signature, which negatively correlates with cancer survival, our findings define a membrane-associated MHC-I inhibitory axis as a potential therapeutic target for both leukemia and solid cancers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37557169/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37557169</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.016>10.1016/j.cell.2023.07.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37557169</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Xufeng Chen</dc:creator>
<dc:creator>Qiao Lu</dc:creator>
<dc:creator>Hua Zhou</dc:creator>
<dc:creator>Jia Liu</dc:creator>
<dc:creator>Bettina Nadorp</dc:creator>
<dc:creator>Audrey Lasry</dc:creator>
<dc:creator>Zhengxi Sun</dc:creator>
<dc:creator>Baoling Lai</dc:creator>
<dc:creator>Gergely Rona</dc:creator>
<dc:creator>Jiangyan Zhang</dc:creator>
<dc:creator>Michael Cammer</dc:creator>
<dc:creator>Kun Wang</dc:creator>
<dc:creator>Wafa Al-Santli</dc:creator>
<dc:creator>Zoe Ciantra</dc:creator>
<dc:creator>Qianjin Guo</dc:creator>
<dc:creator>Jia You</dc:creator>
<dc:creator>Debrup Sengupta</dc:creator>
<dc:creator>Ahmad Boukhris</dc:creator>
<dc:creator>Hongbing Zhang</dc:creator>
<dc:creator>Cheng Liu</dc:creator>
<dc:creator>Peter Cresswell</dc:creator>
<dc:creator>Patricia L M Dahia</dc:creator>
<dc:creator>Michele Pagano</dc:creator>
<dc:creator>Iannis Aifantis</dc:creator>
<dc:creator>Jun Wang</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A membrane-associated MHC-I inhibitory axis for cancer immune evasion</dc:title>
<dc:identifier>pmid:37557169</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.016</dc:identifier>
</item>
<item>
<title>Testosterone and cardiovascular health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37556598/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 9:ehad513. doi: 10.1093/eurheartj/ehad513. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37556598/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37556598</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad513>10.1093/eurheartj/ehad513</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37556598</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrew Elagizi</dc:creator>
<dc:creator>Felice L Gersh</dc:creator>
<dc:creator>Carl J Lavie</dc:creator>
<dc:creator>Jari A Laukkanen</dc:creator>
<dc:creator>James H O'Keefe</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Testosterone and cardiovascular health</dc:title>
<dc:identifier>pmid:37556598</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad513</dc:identifier>
</item>
<item>
<title>Out-of-Hospital Cardiac Arrest-One Size Does Not Fit All</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37556149/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 9. doi: 10.1001/jamacardio.2023.2277. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37556149/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37556149</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2277>10.1001/jamacardio.2023.2277</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37556149</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Nilesh Pareek</dc:creator>
<dc:creator>Thomas R Keeble</dc:creator>
<dc:creator>Shrilla Banerjee</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Out-of-Hospital Cardiac Arrest-One Size Does Not Fit All</dc:title>
<dc:identifier>pmid:37556149</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2277</dc:identifier>
</item>
<item>
<title>Use the Receiver Operating Characteristic to Assess Model Accuracy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37556148/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 9. doi: 10.1001/jamacardio.2023.2250. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37556148/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37556148</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2250>10.1001/jamacardio.2023.2250</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37556148</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Harry B Burke</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Use the Receiver Operating Characteristic to Assess Model Accuracy</dc:title>
<dc:identifier>pmid:37556148</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2250</dc:identifier>
</item>
<item>
<title>Use the Receiver Operating Characteristic to Assess Model Accuracy-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37556135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 9. doi: 10.1001/jamacardio.2023.2247. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37556135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37556135</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2247>10.1001/jamacardio.2023.2247</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37556135</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Xuan Wang</dc:creator>
<dc:creator>Brian Lee Claggett</dc:creator>
<dc:creator>Lu Tian</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Use the Receiver Operating Characteristic to Assess Model Accuracy-Reply</dc:title>
<dc:identifier>pmid:37556135</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2247</dc:identifier>
</item>
<item>
<title>Maternal Risk of Cardiovascular Disease After Use of Assisted Reproductive Technologies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37556134/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: The findings of this study suggest that women who gave birth after ART were not at increased risk of CVD over a median follow-up of 11 years compared with those who conceived without ART. Longer-term studies are needed to further examine whether ART is associated with higher risk of CVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 9. doi: 10.1001/jamacardio.2023.2324. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The use of assisted reproductive technologies (ARTs) is steadily increasing worldwide. The outcomes associated with treatment for an individual's long-term health, including risk of cardiovascular disease (CVD), remain largely unknown, due to the small number of studies and their limited follow-up time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To study whether the risk of CVD is increased among individuals who have given birth after ART compared with those who have given birth without ART.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: A registry-based cohort study was conducted using nationwide data from Denmark (1994-2014), Finland (1990-2014), Norway (1984-2015), and Sweden (1985-2015). Data analysis was conducted from January to August 2022. A total of 2 496 441 individuals with a registered delivery in the national birth registries during the study period were included, and 97 474 (4%) of these gave birth after ART.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Data on ART conception were available from ART quality registries and/or medical birth registries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Information on CVD was available from patient and cause of death registries. The risk of CVD was estimated with Cox proportional hazards regression, adjusting for age, calendar year of start of follow-up, parity, diagnosis of polycystic ovary syndrome, diabetes, chronic hypertension, and country.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Median follow-up was 11 (IQR, 5-18) years. The mean (SD) age of women with no use of ART was 29.1 (4.9) years, and the age of those who used ART was 33.8 (4.7) years. The rate of any CVD was 153 per 100 000 person-years. Individuals who gave birth after using ART had no increased risk of CVD (adjusted hazard ratio [AHR], 0.97; 95% CI, 0.91-1.02), with evidence of heterogeneity between the countries (I2 = 76%; P = .01 for heterogeneity). No significant differences in the risk of ischemic heart disease, cerebrovascular disease, stroke, cardiomyopathy, heart failure, pulmonary embolism, or deep vein thrombosis were noted with use of ART. However, there was a tendency for a modest reduction in the risk of myocardial infarction (AHR, 0.80; 95% CI, 0.65-0.99), with no notable heterogeneity between countries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The findings of this study suggest that women who gave birth after ART were not at increased risk of CVD over a median follow-up of 11 years compared with those who conceived without ART. Longer-term studies are needed to further examine whether ART is associated with higher risk of CVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37556134/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37556134</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2324>10.1001/jamacardio.2023.2324</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37556134</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Maria C Magnus</dc:creator>
<dc:creator>Abigail Fraser</dc:creator>
<dc:creator>Siri E Håberg</dc:creator>
<dc:creator>Kristiina Rönö</dc:creator>
<dc:creator>Liv Bente Romundstad</dc:creator>
<dc:creator>Christina Bergh</dc:creator>
<dc:creator>Anne Lærke Spangmose</dc:creator>
<dc:creator>Anja Pinborg</dc:creator>
<dc:creator>Mika Gissler</dc:creator>
<dc:creator>Ulla-Britt Wennerholm</dc:creator>
<dc:creator>Bjørn Olav Åsvold</dc:creator>
<dc:creator>Deborah A Lawlor</dc:creator>
<dc:creator>Signe Opdahl</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Maternal Risk of Cardiovascular Disease After Use of Assisted Reproductive Technologies</dc:title>
<dc:identifier>pmid:37556134</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2324</dc:identifier>
</item>
<item>
<title>Assisted Reproductive Technologies and Cardiovascular Disease Risk in Birthing Adults-When Null Results Matter</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37556127/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230810100808&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 9. doi: 10.1001/jamacardio.2023.2333. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37556127/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230810100808&v=2.17.9.post6+86293ac">37556127</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2333>10.1001/jamacardio.2023.2333</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37556127</guid>
<pubDate>Wed, 09 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Stephanie A Fisher</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Priya M Freaney</dc:creator>
<dc:date>2023-08-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Assisted Reproductive Technologies and Cardiovascular Disease Risk in Birthing Adults-When Null Results Matter</dc:title>
<dc:identifier>pmid:37556127</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2333</dc:identifier>
</item>





























</channel>
</rss>